Finanzen von AN2 Therapeutics Inc (ANTX)ANTXAN2 Therapeutics Inc

Evaluating the bottom line, AN2 Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -50.12%, provide a clear picture of how effectively ANTX converts its operational activities into shareholder value.

In the context of the broader market, ANTX competes directly with industry leaders such as IPA and CAMP. With a market capitalization of $149.26M, it holds a significant position in the sector. When comparing efficiency, ANTX's gross margin of N/A stands against IPA's 48.31% and CAMP's 100.00%. Such benchmarking helps identify whether AN2 Therapeutics Inc is trading at a premium or discount relative to its financial performance.

ANTX has a current ratio of 14.32, indicating strong liquidity. However, it has reported consistent net losses, with a Q2 2026 loss of $8.2 million, which raises concerns about its profitability.